Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.83 USD | +0.52% | +3.37% | -9.61% |
May. 20 | Foghorn Therapeutics Prices $110 Million Offering of Shares, Pre-Funded Warrants | MT |
May. 06 | Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Chart calendar Foghorn Therapeutics Inc.
Upcoming events on Foghorn Therapeutics Inc.
Past events on Foghorn Therapeutics Inc.
2024-05-06 07:00 am | Q1 2024 Earnings Release |
2024-04-11 11:45 am | Needham Healthcare Conference |
2024-04-10 12:00 pm | American Association for Cancer Research Meeting - Poster No:7185 / 26 |
2024-04-09 05:00 pm | Business Update Call |
2024-04-09 04:30 pm | American Association for Cancer Research Meeting - Poster Number: 6067 / 26 |
2024-04-09 04:30 pm | American Association for Cancer Research Meeting - Poster No: 6064 / 23 |
2024-04-09 01:15 pm | American Association for Cancer Research Meeting - Symposium Session: SY12 |
2024-04-08 09:00 pm | American Association for Cancer Research Meeting - Symposium Session: TM04 |
2024-04-08 04:30 pm | American Association for Cancer Research Meeting - Poster No: 3230 / 14 |
2024-03-07 07:00 am | Q4 2023 Earnings Release |
2024-03-04 12:50 pm | TD Cowen Health Care Conference - Panel |
2023-12-11 09:00 pm | American Society of Hematology Meeting - Publication Number: 4284 |
2023-11-02 01:30 pm | Connective Tissue Oncology Society Meeting - Mike Collins |
2023-11-02 12:00 pm | Connective Tissue Oncology Society Meeting - J. Andrew Livington |
2023-11-02 07:00 am | Q3 2023 Earnings Release |
2023-10-31 02:30 pm | Targeted Protein Degradation Summit - Laura La Bonte |
2023-10-31 09:30 am | Targeted Protein Degradation Summit - Steve Bellon |
2023-10-21 | European Society for Medical Oncology Congress |
2023-10-14 12:30 pm | AACR-NCI-EORTC International Conference - Poster Number: C016 |
2023-10-13 12:30 pm | AACR-NCI-EORTC International Conference - Poster Number: B002 |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,43 0,69 -37.32% | 1,32 0,77 71.97% | 19,2 22,9 -16.11% | 34,2 32,4 5.27% | 23,7 |
EBITDA Million USD | Released Forecast Spread | 0,00 | -67,2 -58,7 -14.46% | -97,5 -67,1 -45.38% | -114 -111 -2.46% | -104 -109 4.19% | -131 |
EBIT Million USD | Released Forecast Spread | 0,00 | -68,5 -62,5 -9.67% | -101 -87,8 -14.72% | -117 -112 -4.43% | -108 -115 6.42% | -119 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -68,8 -65,2 -5.59% | -101 -99,8 -1.5% | -109 -107 -1.99% | -94,2 -105 10.02% | -108 |
Net income Million USD | Released Forecast Spread | -51,1 | -68,8 -65,2 -5.59% | -101 -99,6 -1.72% | -109 -107 -1.69% | -98,4 -105 6.12% | -108 |
EPS USD | Released Forecast Spread | -1,41 | -6,23 -4,99 -24.93% | -2,73 -2,68 -1.87% | -2,62 -2,55 -2.64% | -2,34 -2,49 6.12% | -2,15 |
Announcement Date | 02/10/20 | 18/03/21 | 10/03/22 | 09/03/23 | 07/03/24 | - |
Quarterly results
Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 3,92 11,3 -65.21% | 4,49 8,69 -48.32% | 6,63 9,58 -30.78% | 4,18 10,6 -60.52% | 5,31 5,04 5.39% | 5,60 6,26 -10.6% | 17,5 5,65 209.28% | 5,77 5,78 -0.13% | 5,05 7,35 -31.31% | 6,73 | 6,81 | 7,57 | 9,50 | 9,50 |
EBIT Million USD | Released Forecast Spread | -27,8 -24,4 -13.87% | -29,2 -23,2 -25.95% | -28,3 -25,6 -10.25% | -31,9 -28,9 -10.26% | -33,3 -34,9 4.55% | -32,1 -33,2 3.6% | -17,1 -34,1 49.97% | -25,5 -33,0 22.74% | -28,2 -30,9 8.62% | -30,2 | -30,5 | -30,2 | ||
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -26,9 -20,1 -33.9% | -27,3 -13,6 -100.55% | -25,8 -17,4 -48.16% | -28,9 -23,2 -24.34% | -29,9 -28,6 -4.57% | -28,5 -30,8 7.29% | -13,6 -30,2 54.91% | -22,1 -30,5 27.53% | -25,0 -24,2 -3.37% | -22,1 | -22,3 | -21,5 | ||
Net income Million USD | Released Forecast Spread | -26,9 -20,3 -32.89% | -27,3 -19,6 -39.64% | -25,8 -22,7 -13.48% | -28,9 -24,8 -16.33% | -30,5 -30,2 -0.91% | -29,5 -31,8 7.29% | -14,3 -30,4 52.78% | -24,1 -29,2 17.42% | -25,0 -24,6 -1.53% | -24,2 | -25,1 | -25,4 | ||
EPS USD | Released Forecast Spread | -0,65 -0,43 -52.34% | -0,66 -0,59 -12.34% | -0,62 -0,59 -4.49% | -0,69 -0,62 -10.84% | -0,73 -0,77 4.89% | -0,70 -0,74 4.76% | -0,34 -0,75 54.67% | -0,57 -0,72 20.83% | -0,59 -1,74 66.09% | -0,66 | -0,50 | -0,46 | -0,36 | -0,37 |
Announcement Date | 09/05/22 | 09/08/22 | 08/11/22 | 09/03/23 | 08/05/23 | 04/08/23 | 02/11/23 | 07/03/24 | 06/05/24 | - | - | - | - | - |
Past sector events for Foghorn Therapeutics Inc.
2024-05-17 07:00 am | AUTOLUS THERAPEUTICS PLC: Q1 2024 Earnings Release |
2024-05-16 07:46 am | BIOCON LIMITED: Q4 2024 Earnings Release |
2024-05-16 01:00 am | ZEALAND PHARMA A/S: Q1 2024 Earnings Release |
2024-05-15 | LIGACHEM BIOSCIENCES INC.: Q1 2024 Earnings Release |
2024-05-15 08:05 am | THIRD HARMONIC BIO, INC.: Q1 2024 Earnings Release |
2024-05-15 07:00 am | CABALETTA BIO, INC.: Q1 2024 Earnings Release |
2024-05-14 | TAIMED BIOLOGICS INC.: Q1 2024 Earnings Release |
2024-05-14 04:05 pm | ENLIVEN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-14 04:00 pm | ARCUTIS BIOTHERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-14 08:00 am | IMMUNOME, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- FHTX Stock
- Calendar Foghorn Therapeutics Inc.